Gelonghui November 7th | Beijing Wantai Biological Pharmacy Enterprise (603392.SH) stated on the interactive platform that the Phase II expansion project of the nine-valent cervical cancer vaccine is progressing as planned. The main equipment procurement and workshop purification renovation have been completed, and equipment commissioning and validation are underway. In addition to the flagship product, the nine-valent HPV vaccine, other research and development projects of the company are progressing orderly.
万泰生物(603392.SH)：九价宫颈癌疫苗二期扩产建设项目按计划进行中，已完成主要设备采购及车间净化装修
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): The phase II expansion project of the nine-valent cervical cancer vaccine is proceeding as planned, with the main equipment procurement and workshop purification decoration completed.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated